Last reviewed · How we verify
Topical calcineurin inhibitors
Topical calcineurin inhibitors block the action of calcineurin, a protein involved in the activation of T-cells, thereby reducing inflammation.
Topical calcineurin inhibitors block the action of calcineurin, a protein involved in the activation of T-cells, thereby reducing inflammation. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | Topical calcineurin inhibitors |
|---|---|
| Sponsor | Sanofi |
| Drug class | calcineurin inhibitor |
| Target | calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Calcineurin is a calcium and calmodulin-dependent serine/threonine protein phosphatase that plays a key role in the activation of T-cells. By inhibiting calcineurin, topical calcineurin inhibitors reduce the transcription of IL-2 and other cytokines, leading to decreased inflammation and immune response.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Skin burning sensation
- Redness
- Itching
Key clinical trials
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (PHASE2, PHASE3)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema) (NA)
- A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (PHASE3)
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (PHASE3)
- Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (NA)
- Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical calcineurin inhibitors CI brief — competitive landscape report
- Topical calcineurin inhibitors updates RSS · CI watch RSS
- Sanofi portfolio CI